Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Update on Atopic Dermatitis
Description
In a session on atopic dermatitis led by Dr. Lisa Beck from the University of Rochester, key insights into the condition were shared. Atopic dermatitis is the most common inflammatory skin disorder, primarily affecting children, although a significant portion of cases develops in adulthood. Existing prevalence rates have plateaued in many industrialized nations, and diagnosis can be challenging due to overlapping conditions such as allergic contact dermatitis. The disease presents various clinical features and comorbidities, particularly allergic conditions like asthma and food allergies, as well as psychosocial impacts on patients and their families. The treatment landscape has evolved dramatically since 2016, with the introduction of biologics like dupilumab, oral JAK inhibitors, and topical therapies. Treatment efficacy varies by patient demographics, including age, race, and concurrent health issues. Research indicates that effective management of atopic dermatitis may also reduce bacterial colonization on the skin, thereby improving skin health. Dr. Beck emphasized the importance of ongoing research, highlighting future therapeutic developments aimed at personalizing treatment and potentially altering the progression of related allergic diseases. The session concluded with recognition of the collaborative efforts of researchers and patients in advancing the understanding of atopic dermatitis.
View moreConclusions
- Atopic dermatitis (AD) is the most common inflammatory skin disease, prevalent in 10-20% of children.
- The prevalence of AD has plateaued in developed countries while still increasing in developing countries.
- About 50% of AD cases develop in childhood, with an increasing recognition of adult-onset and late-onset forms.
- Natural resolution occurs in 30-70% of childhood cases, but more severe cases are common in older children and adults, particularly in African American and Hispanic populations.
- AD is associated with various comorbidities, notably asthma, allergic rhinitis, and food allergies, constituting the atopic tetrad.
- AD significantly affects the quality of life, family dynamics, and social functioning, with children often missing school due to their condition.
- Recent advancements in treatment include multiple FDA-approved systemic therapies such as dupilumab, abrocitinib, and upadacitinib, targeting the type 2 immune response.
- New treatment paradigms focus on biologics and JAK inhibitors which show efficacy in improving skin hydration and reducing S. aureus colonization.
- Long-term management of AD includes moisturization as a foundational treatment to improve skin barrier function and minimize flare-ups.
- J Am Acad Dermatol. 2002;46:361.
- Dermatitis. 2014;25:107.
- Pediatr Allergy Immunol. 2015;26:54.
- J Allergy Clin Immunol. 2013;132:1132.
- Allergy 2013;68:498
- Br J Dermatol 2013;168:588
- JAMA Dermatol 2014;150:593.
- Pediatr Dermatol. 2008 Jan-Feb;
- Williams HC, et al. Br J Dermatol. 1994;131:406-416.
- Thyssen JP et al ., JEADV 2020;34:1619.
- J Allergy Clin Immunol. 2004; 113:925
- Allergy 2010;65:1506
- J Allergy Clin Immunol. 2013;131:428
- J Allergy Clin Immunol. 2015;
- JAMA Dermatol 2015:151;522
- J Am Acad Dermatol 2020;83:1282
- Roh Y ... Kwatra S. J Am Acad Dermatol 2022 Apr;86(4):835
- Wan J et al. J Eur Acad Dermatol Venereol. 2022 Aug 26.
- Fivenson D, et al. J Manag Care Pharm. 2002.
- Matthew Ridd, and Sarah Purdy BMJ 2009;339:2997
- Lieberman J et al ., Ann Allergy Asthma. "The available literature on patients who received vaccinations while using dupilumab overall suggests that live vaccines are safe and that the vaccine efficacy, in general, is not affected by dupilumab."
- Gadina M, et al. Rheumatol. 2019;58(Suppl 1):i4-i16.
- Winthrop KL. Nat Rev Rheumatol. 2017;13(4):234-243.
- Howell MD, et al. Front Immunol. 2019;10:2342.
- Silverberg JL et al ., Dermatol Ther (Heidelb) (2025). https://doi.org/10.1007/s13555-025-01357-7.
- Simpson, EL, et al. (2023) J Allergy Clin Immunol. PMID: 37315812.
- Montero-Vilchez T et al ., J. Clin. Med. 2022, 11, 3341.